NEW YORK, June 26, 2017 -- The following statement is being issued by Levi & Korsinsky, LLP:
To: All persons or entities who purchased or otherwise acquired securities of Intra-Cellular Therapies, Inc. ("Intra-Cellular Therapies") (NASDAQ:ITCI) between August 12, 2014 and April 28, 2017. You are hereby notified that a securities class action lawsuit has been commenced in the USDC for the Eastern District of New York. To get more information go to:
http://www.zlk.com/pslra-sb/intra-cellular-therapies-inc?wire=3
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212) 363-7500, toll-free: (877) 363-5972. There is no cost or obligation to you.
The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (1) findings related to toxicity in animals treated with lumateperone (ITI-007) were observed; (2) these findings posed an additional safety concern regarding lumateperone; (3) and as a result of the above, the Company’s public statements were materially false and misleading at all relevant times. On August 4, 2016, the Company’s CEO Sharon Mates touted the “efficacy and safety of ITI-007 for the treatment of schizophrenia.” Then on May 1, 2017, Intra-Cellular disclosed that the U.S. Food and Drug Administration requested information from the Company in order to verify whether or not there are safety risks associated with long term exposure of ITI-007 to patients.
If you suffered a loss in Intra-Cellular Therapies you have until July 11, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.
Levi & Korsinsky is a national firm with offices in New York, California, Connecticut, and Washington D.C. The firm’s attorneys have extensive expertise and experience representing investors in securities litigation, and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Levi & Korsinsky, LLP Joseph E. Levi, Esq. 30 Broad Street - 24th Floor New York, NY 10004 Tel: (212) 363-7500 Toll Free: (877) 363-5972 Fax: (212) 363-7171 www.zlk.com


Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push
UPS and Teamsters Reach Agreement to Limit Driver Severance Program
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
TSMC Japan's Second Fab to Produce 3nm Chips by 2028
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding?
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
China Vanke Seeks Bond Extension Amid Mounting Debt Crisis
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown
Apple Turns 50: From Garage Startup to AI Crossroads
Britain Courts Anthropic Amid US Defense Department Dispute 



